Qusai Alqudah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qusai Alqudah has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ajaypal Gill
Graduate Medical Education, University of Central Florida College of Medicine, Orlando, FL, USA
2 shared publications - Abdalhakim Shubietah
Department of Medicine Advocate Illinois Masonic Medical Center Chicago Illinois USA
1 shared publication - Abdallah Rayyan
Department of Medicine University of Central Florida Orlando Florida USA
1 shared publication - Ahmad Al-Abdouh
Sealy Heart and Vascular Institute University of Texas Medical Branch Galveston Texas USA
1 shared publication - Ahmad Ma'AIta
School of Medicine University of Jordan Amman Jordan
1 shared publication - Andrew Abraham
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA
1 shared publication
Latest Publications
- 12 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Timing of Catheter Ablation After Heart Failure Diagnosis for Atrial Fibrillation: A Propensity‐Score‐Matched Analysis
Background: Catheter ablation improves outcomes in patients with atrial fibrillation (AF) and heart failure (HF). However, most of the evidence on the importance of ablation timing has been anchored to AF rather than HF onset, leaving the optimal interval between HF diagnosis and ablation incompletely defined. Objectives: To evaluate the association between the timing of catheter ablation following the first diagnosis of HF and subsequent clinical outcomes in patients with established AF. Methods: We performed a retrospective propensity‐score‐matched cohort study using the TriNetX Research Network. Adults (≥18 years) with AF who subsequently developed HF and underwent catheter ablation were included. The primary analysis compared ablation from day 1 through 3 months after HF diagnosis with ablation at least 91 days after HF diagnosis. Propensity‐score matching yielded 2,570 patients in each group. Outcomes were assessed for 2 years after ablation and included all‐cause mortality, electrical cardioversion, emergency department or inpatient encounters, and HF exacerbation. A 1‐year timing threshold and analyses stratified by recorded left ventricular ejection fraction were examined as sensitivity analyses. Results: Mean follow‐up was 549.3±253.2 days after early ablation and 534.1±255.3 days after later ablation. Mortality was similar between groups (11.0% vs 10.0%; hazard ratio [HR] 1.078, 95% confidence interval [CI] 0.910–1.276; p = 0.384), as were emergency department or inpatient encounters (66.2% vs 65.6%; HR 1.006, 95% CI 0.940–1.076; p = 0.865). Early ablation was associated with fewer cardioversions (15.0% vs 18.6%; HR 0.788, 95% CI 0.689–0.901; p < 0.001) and fewer HF exacerbation events (39.5% vs 46.0%; HR 0.824, 95% CI 0.758–0.896; p < 0.001). The 1‐year timing analysis showed a similar pattern for cardioversion and the HF exacerbation. Conclusions: Among patients with AF and HF who ultimately underwent ablation, ablation within 3 months of HF diagnosis was associated with fewer subsequent cardioversions and HF exacerbations than ablation performed from day 91 onward. However, there was no significant difference in mortality between the two cohorts. These findings identify the first months after HF diagnosis as a clinically relevant period for reassessing rhythm‐control strategy and warrant prospective evaluation of ablation timing after HF recognition.
- 12 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Timing of Catheter Ablation After Heart Failure Diagnosis for Atrial Fibrillation: A Propensity‐Score‐Matched Analysis
Background: Catheter ablation improves outcomes in patients with atrial fibrillation (AF) and heart failure (HF). However, most of the evidence on the importance of ablation timing has been anchored to AF rather than HF onset, leaving the optimal interval between HF diagnosis and ablation incompletely defined. Objectives: To evaluate the association between the timing of catheter ablation following the first diagnosis of HF and subsequent clinical outcomes in patients with established AF. Methods: We performed a retrospective propensity‐score‐matched cohort study using the TriNetX Research Network. Adults (≥18 years) with AF who subsequently developed HF and underwent catheter ablation were included. The primary analysis compared ablation from day 1 through 3 months after HF diagnosis with ablation at least 91 days after HF diagnosis. Propensity‐score matching yielded 2,570 patients in each group. Outcomes were assessed for 2 years after ablation and included all‐cause mortality, electrical cardioversion, emergency department or inpatient encounters, and HF exacerbation. A 1‐year timing threshold and analyses stratified by recorded left ventricular ejection fraction were examined as sensitivity analyses. Results: Mean follow‐up was 549.3±253.2 days after early ablation and 534.1±255.3 days after later ablation. Mortality was similar between groups (11.0% vs 10.0%; hazard ratio [HR] 1.078, 95% confidence interval [CI] 0.910–1.276; p = 0.384), as were emergency department or inpatient encounters (66.2% vs 65.6%; HR 1.006, 95% CI 0.940–1.076; p = 0.865). Early ablation was associated with fewer cardioversions (15.0% vs 18.6%; HR 0.788, 95% CI 0.689–0.901; p < 0.001) and fewer HF exacerbation events (39.5% vs 46.0%; HR 0.824, 95% CI 0.758–0.896; p < 0.001). The 1‐year timing analysis showed a similar pattern for cardioversion and the HF exacerbation. Conclusions: Among patients with AF and HF who ultimately underwent ablation, ablation within 3 months of HF diagnosis was associated with fewer subsequent cardioversions and HF exacerbations than ablation performed from day 91 onward. However, there was no significant difference in mortality between the two cohorts. These findings identify the first months after HF diagnosis as a clinically relevant period for reassessing rhythm‐control strategy and warrant prospective evaluation of ablation timing after HF recognition.
- Open Access
- 1 January 2026
- Published by XMLink in CardioMetabolic Syndrome Journal
- Vol. 6 (2) , 259
Association Between Pioglitazone Use and Risk of Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Stable Coronary Artery Disease: A Retrospective Analysis From the North Florida Region
Noureldine HA, et al. Cardiometab Syndr J. 2026 ;6:e24. https://doi.org/10.51789/cmsj.2026.6.e24
- 1 January 2026
- Published by XMLink in CardioMetabolic Syndrome Journal
- Vol. 6 (2) , 259
Open AccessAssociation Between Pioglitazone Use and Risk of Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Stable Coronary Artery Disease: A Retrospective Analysis From the North Florida Region
Noureldine HA, et al. Cardiometab Syndr J. 2026 ;6:e24. https://doi.org/10.51789/cmsj.2026.6.e24
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Pulmonology
- Vol. 2025 (1) , 6678388
Primary Lung Adenocarcinoma Manifesting as Bilateral Reticulonodular Infiltrates: A Case Report
A 52‐year‐old female with a history of gastroesophageal reflux disease (GERD), hypertension (HTN), and supraventricular tachycardia (SVT) status postablation presented with progressive dyspnea and diffuse bilateral infiltrates on imaging. Symptoms began following exposure to a chicken farm, initially as a dry cough, evolving despite treatment with antibiotics, albuterol, and methylprednisolone. Emergency department CT imaging demonstrated bilateral linear, reticular, and nodular infiltrates. A negative infectious workup prompted bronchoscopy, confirming lung adenocarcinoma via immunohistochemical staining despite no significant smoking history, international travel, or other exposures. Brain MRI identified a solitary 7‐mm enhancing lesion, guiding subsequent oncologic management. This case underscores the complexity of diagnosing atypical pulmonary symptoms and advocates for early bronchoscopic evaluation in suspected malignancies, particularly with pertinent family history.
- 1 January 2025
- Published by Wiley in Case Reports in Pulmonology
- Vol. 2025 (1) , 6678388
Open AccessPrimary Lung Adenocarcinoma Manifesting as Bilateral Reticulonodular Infiltrates: A Case Report
A 52‐year‐old female with a history of gastroesophageal reflux disease (GERD), hypertension (HTN), and supraventricular tachycardia (SVT) status postablation presented with progressive dyspnea and diffuse bilateral infiltrates on imaging. Symptoms began following exposure to a chicken farm, initially as a dry cough, evolving despite treatment with antibiotics, albuterol, and methylprednisolone. Emergency department CT imaging demonstrated bilateral linear, reticular, and nodular infiltrates. A negative infectious workup prompted bronchoscopy, confirming lung adenocarcinoma via immunohistochemical staining despite no significant smoking history, international travel, or other exposures. Brain MRI identified a solitary 7‐mm enhancing lesion, guiding subsequent oncologic management. This case underscores the complexity of diagnosing atypical pulmonary symptoms and advocates for early bronchoscopic evaluation in suspected malignancies, particularly with pertinent family history.